Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | BlackRock, Inc. BLK | 5,238,400 6.400% | 901,908 (+20.80%) | Filing History |
| 2023-09-11 1:33 pm Purchase | 2023-08-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | VANGUARD GROUP INC | 7,236,523 10.120% | 862,293 (+13.53%) | Filing History |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | T. Rowe Price Associates, Inc. | 4,096,388 5.800% | -1,579,610 (-27.83%) | Filing History |
| 2023-02-14 10:10 am Purchase | 2022-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | RTW Investments, LP | 3,966,915 5.700% | 3,966,915 (New Position) | Filing History |
| 2023-02-09 11:35 am Purchase | 2022-12-30 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | VANGUARD GROUP INC | 6,374,230 9.090% | 453,662 (+7.66%) | Filing History |
| 2023-02-06 2:58 pm Purchase | 2022-12-30 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | Wellington Management Group LLP | 5,202,684 7.420% | 3,918,574 (+305.16%) | Filing History |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | BlackRock, Inc. BLK | 4,336,492 6.200% | 925,078 (+27.12%) | Filing History |
| 2023-01-10 08:47 am Sale | 2022-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | FEDERATED HERMES INC. FHI | 3,094,500 4.410% | -892,370 (-22.38%) | Filing History |
| 2022-12-09 2:31 pm Sale | 2022-12-12 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | Capital International Investors | 1,711,517 2.400% | -3,917,936 (-69.60%) | Filing History |
| 2022-08-10 2:56 pm Sale | 2022-07-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | T. Rowe Price Associates, Inc. | 5,675,998 8.100% | -5,849,091 (-50.75%) | Filing History |
| 2022-03-09 5:18 pm Sale | 2022-02-28 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | BlackRock, Inc. BLK | 3,411,414 4.900% | -73,238 (-2.10%) | Filing History |
| 2022-02-14 3:02 pm Sale | 2021-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | FEDERATED HERMES INC. FHI | 3,986,870 5.850% | -293,658 (-6.86%) | Filing History |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | T. Rowe Price Associates, Inc. | 11,525,089 16.900% | 2,054,597 (+21.69%) | Filing History |
| 2022-02-11 11:19 am Sale | 2022-02-14 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | Capital International Investors | 5,629,453 8.300% | -1,270,040 (-18.41%) | Filing History |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | VANGUARD GROUP INC | 5,920,568 8.690% | 270,183 (+4.78%) | Filing History |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | BlackRock, Inc. BLK | 3,484,652 5.100% | -1,802,824 (-34.10%) | Filing History |
| 2021-10-26 4:44 pm Sale | 2021-10-21 | 13D | ARCTURUS THERAPEUTICS HLDGS IN ARCT | Ultragenyx Pharmaceutical Inc. RARE | 1,200,000 4.600% | -200,000 (-14.29%) | Filing History |
| 2021-10-08 2:08 pm Sale | 2021-10-12 | 13G | ULTRAGENYX PHARMACEUTICAL INC RARE | Capital Research Global Investors | 3,361,792 5.000% | -3,900,109 (-53.71%) | Filing History |